Thrombosis, encompassing arterial and venous thrombosis, and thromboinflammation, impacts the pathophysiology of major health issues such as heart attack, stroke, cancer and infection. Thrombosis contributes to an estimated 40% of cardiovascular deaths in the EU, and over €200 billion a year to the EU economy.

Current therapy in the prevention of arterial thrombotic events includes drugs that suppress platelet function. While effective in a large proportion of patients, a significant number of patients have further thrombotic episodes that result in death, while approximately 5% of treated patients develop clinically relevant bleeding which may require blood transfusion and can be fatal. With an ageing population, who are at a greater risk of thrombosis, the shortfall in available therapy regimes is a growing unmet clinical need in the EU. This presents a major societal problem and a need to develop new and improved anti-platelet agents that effectively target thrombosis whilst preserving haemostasis.  This is the major goal of TAPAS.